Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system.
Saved in:
| Title: | Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system. |
|---|---|
| Authors: | Chang E; Department of Pharmacy, People's Hospital of Zhongjiang County, Deyang, Sichuan, China., Shi YF; College of Pharmacy, Heze University, Heze, Shandong, China., Liu JF; Department of Pharmacy, People's Hospital of Zhongjiang County, Deyang, Sichuan, China., Wei W; Department of Pharmacy, People's Hospital of Zhongjiang County, Deyang, Sichuan, China. |
| Source: | Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Dec; Vol. 23 (12), pp. 1545-1552. Date of Electronic Publication: 2024 May 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1744-764X |
|---|---|
| DOI: | 10.1080/14740338.2024.2351451 |
